Evidence map›Paper›PMID 35372884›Full record

ArticleKidney3602020

Induction and Donor Specific Antibodies in Low Immunologic Risk Kidney Transplant Recipients.

Natalie M Bath, Arjang Djamali, Sandesh Parajuli, Didier Mandelbrot, Glen Leverson, Luis Hidalgo, Thomas Ellis, Jillian L Descourouez, Margaret R Jorgenson, Dave Hager and 2 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Kidney360, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Everolimus plus reduced calcineurin inhibitor preventsFrontiers in transplantation · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Natalie M BathDivision of Transplant, Department of Surgery, University of Wisconsin Hospital and Clinics, Madison, Wisconsin.
Arjang DjamaliDivision of Nephrology, Department of Medicine, University of Wisconsin Hospital and Clinics, Madison, Wisconsin.
Sandesh ParajuliDivision of Nephrology, Department of Medicine, University of Wisconsin Hospital and Clinics, Madison, Wisconsin.
Didier MandelbrotDivision of Nephrology, Department of Medicine, University of Wisconsin Hospital and Clinics, Madison, Wisconsin.
Glen LeversonDepartment of Surgery, University of Wisconsin Hospital and Clinics, Madison, Wisconsin.
Luis HidalgoDivision of Transplant, Department of Surgery, University of Wisconsin Hospital and Clinics, Madison, Wisconsin.
Thomas EllisDepartment of Pathology and Laboratory Medicine, University of Wisconsin Hospital and Clinics, Madison, Wisconsin.
Jillian L DescourouezDivision of Transplant, Department of Surgery, University of Wisconsin Hospital and Clinics, Madison, Wisconsin.
Margaret R JorgensonDivision of Transplant, Department of Surgery, University of Wisconsin Hospital and Clinics, Madison, Wisconsin.
Dave HagerDivision of Transplant, Department of Surgery, University of Wisconsin Hospital and Clinics, Madison, Wisconsin.
Dixon B KaufmanDivision of Transplant, Department of Surgery, University of Wisconsin Hospital and Clinics, Madison, Wisconsin.
Robert R RedfieldDivision of Transplant, Department of Surgery, University of Wisconsin Hospital and Clinics, Madison, Wisconsin.
UW Health University Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Optimal induction for patients without pretransplant donor-specific antibodies (DSAs) is poorly defined. The goal of this study was to compare the incidence of Methods: A retrospective chart review was performed, identifying 782 patients with a negative VXM who underwent kidney transplantation at a single, high-volume institution between January 2013 and May 2017. Kaplan-Meier analysis was used to assess the incidence of dnDSA and allograft survival between induction therapies in this group. dnDSA is defined as the development of new post-transplant DSA, at any MFI level. Results: Induction therapy included alemtuzumab ( Conclusions: In summary, alemtuzumab was associated with a higher rate of dnDSA development in patients with a negative VXM; however, this finding was not associated with rejection or graft failure.

Indexed as

Kidney TransplantationGraft RejectionHumansRetrospective StudiesTissue DonorsTransplant Recipientsantibodiesdonor specific antibodyinductionkidney transplantationtissue donorstransplantation

Identifiers

PMID35372884
PMCPMC8815535
OpenAlexW3091621400

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.